Tysabri (Natalizumab) and PML: What the FDA Prescribing Information Says

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Pharmacovigilance

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). This concern is well-founded, as decades of pharmacovigilance have established a clear link between natalizumab and PML, leading to specific FDA warnings and risk stratification strategies. This page reviews the key elements of the FDA prescribing information, including risk factors and monitoring protocols.

Tysabri and PML: Mechanism, Risk Factors, and FDA Warning

Tysabri (natalizumab) is a monoclonal antibody indicated for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus. The U.S. Food and Drug Administration (FDA) has issued a boxed warning highlighting this risk, which is the strongest safety alert for a prescription medication. The boxed warning states that Tysabri increases the risk of PML, an infection that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three primary risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against the expected benefit when initiating or continuing therapy. The mechanistic pathway linking Tysabri to PML involves its pharmacological action. Tysabri binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier. This reduces inflammation in the central nervous system but also impairs immune surveillance, allowing latent JC virus to reactivate and cause PML. The virus typically only causes disease in immunocompromised individuals, and Tysabri-induced immune suppression creates a permissive environment for viral replication.

Clinical Presentation, Diagnosis, and Risk Mitigation

Clinical presentation of PML includes progressive neurological deficits such as weakness, cognitive impairment, vision changes, and speech difficulties. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. The FDA boxed warning emphasizes that healthcare professionals should monitor patients for any new signs or symptoms suggestive of PML and withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of this risk, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1869 multiple sclerosis patients treated for a median of 120 weeks, and both had also received interferon beta-1a (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The third case occurred after eight doses in one of 1043 Crohn's disease patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These data underscore that PML risk increases with longer exposure, particularly beyond two years.

Causation and Evidence from Adverse Event Reports

The adequacy of warnings regarding Tysabri and PML is a critical risk consideration. The boxed warning clearly communicates the increased risk, identifies known risk factors, and mandates monitoring and immediate discontinuation if PML is suspected. However, the warning also notes that these factors should be considered in the context of expected benefit, which may lead to variability in risk assessment and communication between clinicians and patients. For affected patients, causation considerations involve establishing a temporal relationship between Tysabri exposure and PML onset, as well as ruling out other causes of immunosuppression. The timeline between exposure and documented harm can vary; PML has been reported after as few as eight doses and after longer treatment durations. Adverse event reports from the FDA Adverse Event Reporting System (FAERS) list fatigue, multiple sclerosis relapse, headache, and gait disturbance among the most frequently reported events with Tysabri (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not directly quantify PML incidence, they reflect the broader safety profile of the drug. In summary, the evidence establishes a clear causal link between Tysabri and PML, supported by pharmacological mechanism, clinical trial data, and FDA warnings. Risk factors are well-defined, and the boxed warning provides guidance for risk mitigation. For patients who develop PML, the outcome is often severe, and early recognition and discontinuation of Tysabri are critical.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the FDA boxed warning for Tysabri regarding PML?

The FDA boxed warning states that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability. The warning identifies three primary risk factors: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. Healthcare professionals are advised to monitor patients for new signs or symptoms of PML and to withhold Tysabri immediately if PML is suspected. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962)

How does Tysabri cause PML?

Tysabri binds to alpha-4 integrins on immune cells, preventing their migration across the blood-brain barrier. This reduces inflammation in the central nervous system but also impairs immune surveillance, allowing latent JC virus to reactivate and cause PML. The virus typically only causes disease in immunocompromised individuals, and Tysabri-induced immune suppression creates a permissive environment for viral replication.

What are the symptoms and diagnosis of PML?

Clinical presentation includes progressive neurological deficits such as weakness, cognitive impairment, vision changes, and speech difficulties. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. Early recognition is critical for patient outcomes.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.